The Homeopathic Pharmacopeia of the United States has posted two new documents to the HPUS. These documents and their guidance information are essential to your business, your cGMP compliance, your products and your long-term success in the market!
Attend AAHP’s next Compliance Thru Education webinar on Thursday, May 18, 2017 at 1:00 p.m. ET • 12:00 p.m. CT • 11:00 a.m. MT • 10:00 a.m. PT to introduce and prepare you to make use of these documents.
PRESENTER: Eric Foxman, RPh, a founding member of the Homeopathic Pharmacopeia Convention of the United States.
COST: Non-Members: $199. AAHP members get a $90 discount code available from the AAHP office.
REGISTRATION: Please use the following link to register for this webinar. You will receive an email confirmation shortly after you complete the registration.
For more information regarding the seminar, call Eric Foxman (1-503-659-2715) or by email: firstname.lastname@example.org
The AAHP NetworkNews had a quick conversation with presenter Eric L. Foxman about what will be covered in the webinar.
NetworkNews: In a nutshell, what are you going to talk about?
Eric L. Foxman: The Homeopathic Pharmacopeia of the United States has posted two new documents to the HPUS. These documents and the guidance information in them are essential for every homeopathic company. Whether a company manufactures or just markets homeopathic drug products, the new information in the HPUS has a bearing on every product’s compliance status.
NN: What are those two documents?
ELF: The first is a major revision of the HPUS Homeopathic Good Manufacturing Practices Guidelines. At first glance, it is obviously much longer. But it’s more than just verbiage. A closer examination reveals the previous version touched on about 40 important considerations; the revision addresses more than 175 points that manufacturers and marketers need to be aware of.
NN: And the other document?
ELF: This is a brand new document for the HPUS, entitled Homeopathic Drug Stability Guidelines. It addresses issues concerning stability testing and retest periods; these are subjects that directly impact every homeopathic product marketed in the U.S.
NN: What else will you address in the webinar?
ELF: There are a few new monographs that have been approved for publication, and more than four-dozen additional monographs now have quality control specifications. I’ll touch on an update to the alcohol coefficients in the Guidelines for Manufacturing Homeopathic Medicines, as well as the results of discussions the Convention has had regarding California’s Proposition 65 and its impact on OTC attenuations. And perhaps the most important subject will be the implementation timeline of the HPUS Expanded Labeling Guidelines.
NN: How long will the webinar be?
ELF: I am going to keep it to an hour to make it possible for the most people to participate within their busy schedules. Thus, I will be providing an overview on all these subjects but am also working to prepare downloadable documents that provide more detail on the scope of the additions and changes. For instance, there will be a downloadable document that provides an outline comparison between the subjects covered in the previous Homeopathic GMPS document and the newly revised version. My intention is to provide attendees with a solid introduction so they can best make use of these documents. The information in these documents is essential for every homeopathic business to ensure the products they bring to market meet reasonable and appropriate expectations for homeopathic drug products while assuring a consistent level of quality.
NN: This is the fourth webinar you have presented on the HPUS for the AAHP. How long have you been involved with the Homeopathic Pharmacopeia?
ELF: I am what one might call a charter member of the HPCUS. Looking back, I realize that I have been involved with the Pharmacopeia Convention for 37 years – since its establishment in 1980. For many years, I was the chair of the Pharmacopeia Revision Committee. I am now in my 10th year on the Board of Trustees of the HPCUS and for almost as long I have served as the Chair of the Council on Pharmacy. In these capacities, I am active in the ongoing revision and updating of the contents of the HPUS. I also serve on the Monograph Review Committee, and continue, after more than a quarter century, on the Standards and Controls Committee. I guess that’s why I feel comfortable sharing these updates with the homeopathic industry.